Energenesis Biomedical CO.,LTD.
Research Energenesis Biomedical CO.,LTD. (6657.TW) on Bullrun: market cap TWD 2.87B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6657.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 2.87B
- Financial periodQ2 2026
- RevenueTWD 1.85M
- Net income-TWD 138.50M
- Free cash flow-TWD 96.34M
- Gross margin69.7%
Valuation Snapshot
latest market cap is TWD 2.87B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 2.87B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Energenesis Biomedical CO.,LTD.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases;
ETFs that hold Energenesis Biomedical CO.,LTD.
US-listed ETFs
Energenesis Biomedical CO.,LTD. is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Energenesis Biomedical CO.,LTD.'s market cap?
Energenesis Biomedical CO.,LTD.'s market capitalization is TWD 2.87B.
What does Energenesis Biomedical CO.,LTD. do?
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for.